Genentech and PeptiDream to co-develop radiopharmaceuticals in $1BN deal

The Roche-owned U.S. giant Genentech has teamed up with the Japanese biotech Peptidream to co-develop peptide-based radiopharmaceutical treatments.

Related Keywords

Japan ,Canada ,Patrick Reid ,Nasdaq ,Fusion Pharmaceuticals ,Genentech ,Peptide Discovery Platform System ,Ono Pharmaceutical ,Markets Amp Regulations ,Emerging Markets ,Peptide ,Radiopharmaceuticals ,Research ,Oche ,